Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Demonstrate Lot-to-Lot Consistency of 3 Lots of a Tetravalent Dengue Vaccine Candidate in Healthy Adults in Non-Endemic Country(Ies) for Dengue
Conditions
Interventions
TAK-003
Placebo
Locations
14
United States
Optimal Research
Huntsville, Alabama, United States
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Advanced Clinical Research
Boise, Idaho, United States
Optimal Research
Peoria, Illinois, United States
Synexus Limited- Council Bluffs
Council Bluffs, Iowa, United States
Heartland Research Associates LLC - Augusta
Augusta, Kansas, United States
Start Date
February 12, 2018
Primary Completion Date
August 3, 2018
Completion Date
January 14, 2019
Last Updated
October 20, 2020
NCT06579755
NCT07007585
NCT06665035
NCT06388785
NCT07432061
NCT06741683
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions